Beam Therapeutics Inc.

BEAM

Precision medicineBiotech & pharmaceuticals

$28.55vs prev close▼-1.21(-4.07%)

$16.0252W Range$38.26

56% from low

+3.30 (+13.15%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

1.83%

1M -0.36%p

Holding ETFs

2 ETFs

ARKG · ARKK

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -1.7% · Market value -24.6% · Weight -0.36%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.07.16	BUY	ARKG	29,375	$28.39	$834.0K
26.07.15	BUY	ARKG	32,751	$30.84	$1.0M
26.07.14	BUY	ARKG	14,820	$30.89	$457.8K
26.07.13	BUY	ARKG	82,392	$31.00	$2.6M
26.06.09	BUY	ARKK	21,873	$30.47	$666.5K
26.06.08	BUY	ARKK	15,114	$29.78	$450.1K
26.06.05	BUY	ARKK	87,414	$29.40	$2.6M
26.03.25	SELL	ARKK	99,745	$23.12	$2.3M
26.03.24	SELL	ARKK	27,716	$23.95	$663.8K
26.02.26	SELL	ARKK	113,970	$28.92	$3.3M
26.02.25	SELL	ARKG · ARKK	16,993	$29.61	$503.2K
26.02.13	BUY	ARKG · ARKK	218,529	$27.92	$6.1M
26.02.12	BUY	ARKG · ARKK	38,254	$26.93	$1.0M
26.01.29	BUY	ARKG · ARKK	29,413	$29.29	$861.5K
26.01.28	BUY	ARKG · ARKK	116,386	$29.02	$3.4M

07.16BUY

29,375

ARKGClose$28.39Est. total$834.0K

07.15BUY

32,751

ARKGClose$30.84Est. total$1.0M

07.14BUY

14,820

ARKGClose$30.89Est. total$457.8K

07.13BUY

82,392

ARKGClose$31.00Est. total$2.6M

06.09BUY

21,873

ARKKClose$30.47Est. total$666.5K

06.08BUY

15,114

ARKKClose$29.78Est. total$450.1K

06.05BUY

87,414

ARKKClose$29.40Est. total$2.6M

03.25SELL

99,745

ARKKClose$23.12Est. total$2.3M

03.24SELL

27,716

ARKKClose$23.95Est. total$663.8K

02.26SELL

113,970

ARKKClose$28.92Est. total$3.3M

02.25SELL

16,993

ARKG · ARKKClose$29.61Est. total$503.2K

02.13BUY

218,529

ARKG · ARKKClose$27.92Est. total$6.1M

02.12BUY

38,254

ARKG · ARKKClose$26.93Est. total$1.0M

01.29BUY

29,413

ARKG · ARKKClose$29.29Est. total$861.5K

01.28BUY

116,386

ARKG · ARKKClose$29.02Est. total$3.4M

1 / 10

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

8,370,380

Portfolio Weight

1.83%

in ETF 3.75%

Est. Value

$227M

30D Net

+$5M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Hold

Analyst Targets

avg.

$52.15

vs Current ▲ +96.3% upside

Current$26.57

Low ~ High$26.00 ~ $80.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

B of A Securities

Buy

$47.00

+76.89%

—

Maintain

2026-07-08

HC Wainwright & Co.

Buy

$80.00

+201.09%

—

Maintain

2026-07-07

Bernstein

Outperform

$39.00

+46.78%

—

Maintain

2026-05-13

Citigroup

Buy

$68.00

+155.93%

—

Maintain

2026-03-26

RBC Capital

Sector Perform

$26.00

-2.15%

—

Maintain

2026-02-25

1 / 4

Avg Target

$52.15

vs Current ▲ +96.3% upside

Strong Buy

15 analysts

Strong Buy 1Buy 12Hold 2

Low $26.00

Current $26.57

High $80.00

Firm	Position	Target	Upside	Close	Action	Date
B of A Securities	Buy	$47.00	+76.89%	—	Maintain	26.07.08
HC Wainwright & Co.	Buy	$80.00	+201.09%	—	Maintain	26.07.07
Bernstein	Outperform	$39.00	+46.78%	—	Maintain	26.05.13
Citigroup	Buy	$68.00	+155.93%	—	Maintain	26.03.26
RBC Capital	Sector Perform	$26.00	-2.15%	—	Maintain	26.02.25

1 / 4

Price Information

Previous Close$29.76

Open$28.74

Day Range$28.61 - $30.50

52-Week Range$16.02 - $38.26

1-Year Change81.02%

Trading Volume

Volume2,447,428

Avg Volume (3mo)2,180,717

Valuation

Market Cap3.1B

Book Value$10.69

Shares Outstanding103,287,665

Financials

Revenue (TTM)156.0M

Net Income-86,520,000

EPS$-0.69

EBITDA-355,780,992

Profitability

P/E Ratio-

P/B Ratio2.79

Return on Equity (ROE)-8.18%

Return on Assets (ROA)-17.01%

Profit Margin-55.45%

EV/EBITDA-5.81

Beta2.21

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)67.87

Company Overview

Beam Therapeutics is a biotechnology company developing precision genetic medicines for serious diseases. Their main products include novel base editing therapies for sickle cell disease, alpha-1 antitrypsin deficiency, and glycogen storage disease 1a, with a pipeline targeting various genetic disorders. Beam is positioned as an innovator in the field of genetic medicine, with strategic collaborations with major pharmaceutical companies.

P/B

2.79

Price-to-Book

ROE

-8.2%

Net loss

Beta

2.21

Extreme volatility

RSI(14)

67.9

Neutral zone

AI-generated summary. Not investment advice.

Beam Therapeutics Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks